Characteristics of COVID-19 and Impact of Disease Activity in Patients with Adult-Onset Still's Disease
Description
CONCLUSION: Patients with AOSD receiving medium or high-dose glucocorticoid therapy or JAK inhibitors had worse COVID-19 outcomes. Further work is needed to explore risk factors affecting COVID-19 outcomes and the impact of COVID-19 on disease
